heart failure and iron deficiency
Conditions
Interventions
Experimental group: intravenous iron sucrose
Sponsors
Qingdao Municipal Hospital group
Eligibility
Sex/Gender
All
Age
65 Years to 102 Years
Inclusion criteria
Inclusion criteria: (1) heart failure symptoms, signs and N terminal b-type natriuretic peptide (NT - proBNP) was higher; (2) aged >65 years, left ventricular ejection fraction; (3) Serum ferritin=90g/L;
Exclusion criteria
Exclusion criteria: (1) gastrointestinal bleeding, menorrhagia, no healing or inflammatory bowel related peptic ulcer; (2) the uncorrected hypothyroidism; (3) inflammatory, tumor, or other infectious diseases; (4) severe renal dysfunction, blood system diseases, severe liver function damage; (5) to form of oral intolerance elemental iron compounds; (6) alcoholic cardiomyopathy caused by heart failure or 1 month ago because of decompensated heart failure on admission; (7) for nearly three months of coronary artery bypass graft, percutaneous coronary angioplasty or heart cavity device implantation (including cardiac resynchronization therapy); (8) for nearly three months of acute coronary syndrome, stroke or transient ischemic attack; (9) malignant tumour of the life expectancy of less than one year; (10) Heart transplant patients; (11) Within 3 months to use to promote preparations, intravenous iron erythropoiesis transfusions, or oral iron preparations and four weeks (> 100 mg/d).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a composite of total heart failure hospitalizations and cardiovascular death up to 52 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| heart failure hospitalizations;;cardiovascular death;first heart failure hospitalization or cardiovascular death;Cardiac function;Anemia and iron deficiency related indicators;Liver function; | — |
Countries
China
Contacts
Public ContactWang Mengjuan
Qingdao Municipal Hospital group
Outcome results
None listed